Cynosure (NASDAQ: CYNO) and Koninklijke Philips (NYSE:PHG) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.
Earnings and Valuation
This table compares Cynosure and Koninklijke Philips’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Koninklijke Philips||$20.08 billion||1.82||$1.87 billion||$2.03||19.21|
Koninklijke Philips pays an annual dividend of $0.73 per share and has a dividend yield of 1.9%. Cynosure does not pay a dividend. Koninklijke Philips pays out 36.0% of its earnings in the form of a dividend.
This table compares Cynosure and Koninklijke Philips’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Cynosure and Koninklijke Philips, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cynosure presently has a consensus price target of $66.00, indicating a potential upside of Infinity. Koninklijke Philips has a consensus price target of $37.00, indicating a potential downside of 5.10%. Given Cynosure’s higher possible upside, analysts plainly believe Cynosure is more favorable than Koninklijke Philips.
Institutional and Insider Ownership
6.5% of Koninklijke Philips shares are held by institutional investors. 2.9% of Cynosure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Koninklijke Philips beats Cynosure on 9 of the 13 factors compared between the two stocks.
Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
About Koninklijke Philips
Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company’s segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.
Receive News & Ratings for Cynosure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure and related companies with MarketBeat.com's FREE daily email newsletter.